Screener
Ligand Pharmaceuticals LGND Impairment Charges
Discontinued — last reported Q4 '25
Impairment Charges at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill.
The source filing: Ligand Pharmaceuticals’s 10-K, filed February 27, 2026.
- Filed
- Feb 27, 2026, 4:02 PM EST
- Fiscal year
- FY2025
- Accession
- 0000886163-26-000006
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Amortization of intangibles | 32,708 | 32,959 | 33,654 |
| Research and development | 81,182 | 21,425 | 24,537 |
| General and administrative | 92,449 | 78,654 | 52,790 |
| Financial royalty assets impairment | 6,197 | 30,572 | — |
| Fair value adjustments to partner program derivatives | — | 15,055 | — |
| Total operating costs and expenses | 227,085 | 189,739 | 121,493 |
| Gain on sale of Pelican | — | — | (2,121) |
| Operating income (loss) from continuing operations | 41,002 | (22,606) | 11,942 |
Item 8. Consolidated Financial Statements and Supplementary Data
FAQ
- What is Ligand Pharmaceuticals's impairment charges?
- Ligand Pharmaceuticals (LGND) reported impairment charges of $6.2M in Q4 2025.
- How has Ligand Pharmaceuticals's impairment charges changed year-over-year?
- Ligand Pharmaceuticals's impairment charges increased by 51.9% year-over-year, from $4.08M to $6.2M.
- What does impairment charges mean?
- Write-downs of long-lived assets (excluding goodwill) when their carrying value exceeds fair value, including property, equipment, right-of-use assets, and other tangible assets.
Ask your AI about Ligand Pharmaceuticals's impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude